Risk factors for interstitial lung disease in rheumatoid arthritis: a cohort study from the KOBIO registry

被引:1
作者
Min, Hong Ki [1 ]
Kim, Se Hee [1 ,2 ]
Lee, Sang-Heon [3 ]
Kim, Hae-Rim [4 ]
机构
[1] Konkuk Univ, Med Ctr, Dept Internal Med, Div Rheumatol, Seoul, South Korea
[2] Kyung Hee Univ, Kyung Hee Univ Hosp Gangdong, Coll Med, Dept Rheumatol, Seoul, South Korea
[3] Konkuk Univ, Sch Med, Res Inst Med Sci, Div Rheumatol,Dept Internal Med,Med Ctr, Seoul, South Korea
[4] Konkuk Univ, Sch Med, Med Ctr, Div Rheumatol,Dept Internal Med,Res Inst Med Sci, 120-1 Neungdong Ro, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
biologics; DAS28; DMARDs; interstitial lung disease; rheumatoid arthritis; rheumatoid factor; AMERICAN-COLLEGE; EPIDEMIOLOGY; ABATACEPT; EVENTS;
D O I
10.1177/1759720X231218098
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Interstitial lung disease (ILD) is a critical extra-articular manifestation of rheumatoid arthritis (RA). However, little is known about the risk factors of RA-ILD.Objectives: Here, we examined the effect of demographic, clinical, therapeutic, and environmental factors on the incidence of ILD in RA patients using the Korean College of Rheumatology Biologics and Targeted Therapy (KOBIO) registry.Design: We used data from the KOBIO registry, a multi-center, prospective, observational cohort that included RA patients in South Korea.Methods: RA patients who used biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) or conventional synthetic (cs)DMARDs, and were enrolled in the KOBIO registry, were examined. Demographic, clinical, and radiographic characteristics, as well as medications, were recorded at baseline and annually thereafter. Kaplan-Meier curves and the log-rank test were used to compare the incidence of ILD between RA patients taking different b/tsDMARDs. Hazard ratios (HRs) were calculated by Cox regression analyses.Results: In total, 2492 patients (1967 in the b/tsDMARDs group and 525 in the csDMARDs group) were analyzed. The b/tsDMARDs group showed longer disease duration, higher erythrocyte sedimentation rate/C-reactive protein, and higher disease activity score-28 (DAS28) than the csDMARDs group. The incidence of ILD was significantly higher in those taking tumor necrosis factor inhibitors and abatacept than in those taking csDMARDs (log ranked p < 0.001). Multivariate Cox regression analysis identified older age (HR = 1.057, p = 0.001), male sex (HR = 2.824, p = 0.007), time-averaged DAS28 (HR = 2.241, p < 0.001), and rheumatoid factor titer (HR = 1.009, p = 0.007) as having a significantly increased HR for ILD occurrence.Conclusion: ILD is a rare but critical extra-articular symptom of RA patients. Therefore, RA patients with the above risk factors should be monitored carefully for ILD development.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Genetic, social, and environmental risk factors in rheumatoid arthritis-associated interstitial lung disease
    Wheeler, Austin M.
    Baker, Joshua F.
    Poole, Jill A.
    Ascherman, Dana P.
    Yang, Yangyuna
    Kerr, Gail S.
    Reimold, Andreas
    Kunkel, Gary
    Cannon, Grant W.
    Wysham, Katherine D.
    Singh, Namrata
    Lazaro, Deana
    Monach, Paul
    Bridges, S. Louis
    Mikuls, Ted R.
    England, Bryant R.
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2022, 57
  • [22] Analysis of comorbidity in rheumatoid arthritis-associated interstitial lung disease: a nested case-cohort study
    Mena-Vazquez, Natalia
    Rojas-Gimenez, Marta
    Maria Romero-Barco, Carmen
    Gandia-Martinez, Myriam
    Perez-Gomez, Nair
    Javier Godoy-Navarrete, Francisco
    Manrique-Arija, Sara
    Garcia-Studer, Aimara
    Calvo-Gutierrez, Jerusalem
    Fuego Varela, Clara
    Morales-Garrido, Pilar
    Castro Perez, Patricia
    Mourino-Rodriguez, Coral
    Anon-Onate, Isabel
    Espildora, Francisco
    Carmen Aguilar-Hurtado, Maria
    Redondo, Rocio
    Hidalgo Conde, Ana
    Diez de los Rios, Rocio Arnedo
    Cabrera Cesar, Eva
    Luisa Velloso-Feijoo, Maria
    Fernandez-Nebro, Antonio
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 157
  • [23] Impact of concomitant methotrexate on disease activity in patients with rheumatoid arthritis tapering abatacept: results from KOBIO registry
    Park, Jun Won
    Kim, Ju Yeon
    Kim, Min Jung
    Lim, Yoo Kyoung
    Kim, Hyoun-Ah
    Kim, Jin Hyun
    Shin, Kichul
    FRONTIERS IN MEDICINE, 2024, 11
  • [24] Targeted Therapy in Rheumatoid-Arthritis-Related Interstitial Lung Disease
    Harrington, Robert
    Harkins, Patricia
    Conway, Richard
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (20)
  • [25] Protective effect of methotrexate on lung function and mortality in rheumatoid arthritis-related interstitial lung disease: a retrospective cohort study
    Kim, Kangjoon
    Woo, Ala
    Park, Youngmok
    Yong, Seung Hyun
    Lee, Su Hwan
    Lee, Sang Hoon
    Leem, Ah Young
    Kim, Song Yee
    Chung, Kyung Soo
    Kim, Eun Young
    Jung, Ji Ye
    Kang, Young Ae
    Kim, Young Sam
    Park, Moo Suk
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2022, 16
  • [26] Abatacept in patients with rheumatoid arthritis and interstitial lung disease: A national multicenter study of 63 patients
    Fernandez-Diaz, Carlos
    Loricera, Javier
    Castaneda, Santos
    Lopez-Mejias, Raquel
    Ojeda-Garcia, Clara
    Olive, Alejandro
    Rodriguez-Muguruza, Samantha
    Carreira, Patricia E.
    Perez-Sandoval, Trinidad
    Retuerto, Miriam
    Cervantes-Perez, Evelin C.
    Flores-Robles, Bryan J.
    Hernandez-Cruz, Blanca
    Urruticoechea, Ana
    Maiz-Alonso, Olga
    Arboleya, Luis
    Bonilla, Gema
    Hernandez-Rodriguez, Inigo
    Palma, Desiree
    Delgado, Concepcion
    Exposito-Molinero, Rosa
    Ruibal-Escribano, Ana
    Alvarez-Rodriguez, Belen
    Blanco-Madrigal, Juan
    Bernal, Jose A.
    Vela-Casasempere, Paloma
    Rodriguez-Gomez, Manuel
    Fito, Concepcion
    Ortiz-Sanjuan, Francisco
    Narvaez, Javier
    Moreno, Manuel
    Lopez-Corbeto, Mireia
    Mena-Vazquez, Natalia
    Aguilera-Cros, Clara
    Romero-Yuste, Susana
    Ordonez, Sergi
    Villa-Blanco, Ignacio
    Carmen Gonzelez-Vela, M.
    Mora-Cuesta, Victor
    Palmou-Fontana, Natalia
    Hernandez, Jose L.
    Gonzalez-Gay, Miguel A.
    Blanco, Ricardo
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2018, 48 (01) : 22 - 27
  • [27] Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry
    Park, Dong-Jin
    Choi, Sung Jae
    Shin, Kichul
    Kim, Hyoun-Ah
    Park, Yong-Beom
    Kang, Seong Wook
    Kwok, Seung-Ki
    Kim, Seong-Kyu
    Nam, Eon Jeong
    Sung, Yoon-Kyoung
    Lee, Jaejoon
    Lee, Chang Hoon
    Jeon, Chan Hong
    Lee, Shin-Seok
    CLINICAL RHEUMATOLOGY, 2017, 36 (05) : 1013 - 1022
  • [28] Serum alarmins and the risk of incident interstitial lung disease in rheumatoid arthritis
    Poole, Jill A.
    England, Bryant R.
    Sayles, Harlan
    Johnson, Tate M.
    Duryee, Michael J.
    Hunter, Carlos D.
    Baker, Joshua F.
    Kerr, Gail S.
    Kunkel, Gary
    Cannon, Grant W.
    Sauer, Brian C.
    Wysham, Katherine D.
    Joseph, Amy M.
    Wallace, Beth, I
    Thiele, Geoffrey M.
    Mikuls, Ted R.
    RHEUMATOLOGY, 2023, : 1998 - 2005
  • [29] Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study
    Manfredi, Andreina
    Cassone, Giulia
    Furini, Federica
    Gremese, Elisa
    Venerito, Vincenzo
    Atzeni, Fabiola
    Arrigoni, Eugenio
    Della Casa, Giovanni
    Cerri, Stefania
    Govoni, Marcello
    Petricca, Luca
    Iannone, Florenzo
    Salvarani, Carlo
    Sebastiani, Marco
    INTERNAL MEDICINE JOURNAL, 2020, 50 (09) : 1085 - 1090
  • [30] Serum alarmins and the risk of incident interstitial lung disease in rheumatoid arthritis
    Poole, Jill A.
    England, Bryant R.
    Sayles, Harlan
    Johnson, Tate M.
    Duryee, Michael J.
    Hunter, Carlos D.
    Baker, Joshua F.
    Kerr, Gail S.
    Kunkel, Gary
    Cannon, Grant W.
    Sauer, Brian C.
    Wysham, Katherine D.
    Joseph, Amy M.
    Wallace, Beth I.
    Thiele, Geoffrey M.
    Mikuls, Ted R.
    RHEUMATOLOGY, 2023, 63 (07) : 1998 - 2005